Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company (BMY) reports on events occurring on November 9, 2020, with the report dated November 13, 2020. The filing details the completion of a public offering of senior notes to fund a portion of the cash consideration for the proposed acquisition of MyoKardia, Inc., expected to close in the fourth quarter of 2020.
Key Financial Metrics
The Company completed a multi-tranche debt offering with an aggregate principal amount of $7.0 billion. The specific tranches issued are as follows:
- 2023 Notes: $1.5 billion at 0.537% interest.
- 2025 Notes: $1.0 billion at 0.750% interest.
- 2027 Notes: $1.0 billion at 1.125% interest.
- 2030 Notes: $1.25 billion at 1.450% interest.
- 2040 Notes: $0.75 billion at 2.350% interest.
- 2050 Notes: $1.5 billion at 2.550% interest.
Interest payments are scheduled semi-annually on May 13 and November 13, commencing May 13, 2021. The filing does not provide specific revenue, profit, cash flow, or margin data for the period, as this is a current report regarding a specific financing event rather than a periodic financial statement.
Material Changes and Use of Proceeds
The primary material change is the increase in long-term debt obligations by $7.0 billion. The net proceeds from the offering are designated to fund a portion of the aggregate cash consideration for the MyoKardia acquisition and to pay related fees and expenses. Any remaining proceeds will be used for general corporate purposes. The offering is not conditioned on the consummation of the acquisition.
Outlook, Risks, and Contingencies
Redemption Contingency: A special mandatory redemption clause applies if the MyoKardia acquisition is not consummated by June 30, 2021, or if the Company notifies the trustee prior to that date that it will not pursue the acquisition. In such an event, the Company must redeem all outstanding Notes at 101% of the aggregate principal amount plus accrued interest.
Call Provisions: The 2023 Notes are not redeemable prior to November 13, 2021. Other tranches may be redeemed prior to their Par Call Date at a make-whole premium or at par after the applicable Par Call Date.
Covenants: The Indenture includes customary covenants restricting the Company's ability to incur secured debt, engage in sale/leaseback transactions, or merge without satisfying certain conditions.
Investor Verification Checklist
- Verify the closing status and timeline of the MyoKardia, Inc. acquisition to assess the risk of the special mandatory redemption.
- Review the full text of the Twelfth Supplemental Indenture (Exhibit 4.1) for detailed covenants and default events.
- Confirm the final net proceeds received after deducting underwriting fees and expenses.
- Monitor the Company's liquidity position to ensure it can service the new $7.0 billion debt load alongside existing obligations.